EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation

Michelle Jun, Harlan Pinto, Quynh-Thu Le iD, Andrew Quon, Wendy Hara, Jessie Coty, Alex McMillan, Rong Lu iD, Elzbieta Winters, Ruth Lira, A Dimitrios Colevas iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0276651 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift PLOS ONE, 2023. Verfasst von Michelle Jun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Institute, Stanford University, Stanford, California, United States of America. Hauptthemen laut MEDLINE: Induction Chemotherapy, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: school of medicine, stanford university.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

A phase II = design is used to evaluate the efficacy and feasibility of full dose docetaxel, platinum, and 5-fluorouracil (TPF) in a sequential chemoradiation treatment locally advanced (LA) or oligometastatic (OM) NPC patients. Materials and methods Twenty patients with LANPC (M0 cohort) and six patients with OMNPC (M1 cohort) received induction standard dose T (75 mg/m2) P (75 mg/m2) F (750 mg/m2 IVCI x 5days) x 3 followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) x 6 concurrent with radiation therapy of 70 Gy over 6.5–7 weeks. The first five patients received bevacizumab as part of an exploratory objective of hypoxia modification using correlative fluoromisonidasole ( 18 F-MISO) PET CT scanning.

Results

The 18 F-MISO imaging failed to reveal adequate levels of baseline hypoxia necessary to evaluate for changes with chemotherapy and bevacizumab. Ninety percent of M0 patients and 83% of M1 patients received the full-intended TPF and radiation dose. Eighty-five percent of M0 patients and all M1 patients received at least 60% of the full-intended concurrent platinum dose. The 2-year progression free survival (PFS) rate for the M0 cohort was 90% (95% CI: 77.8%– 100%), and was sustained at 5 years. The 2-year PFS rate for the M1 cohort was 66.7% (95% CI: 37.9%– 100%). The 2-year overall survival (OS) rates for the M0 and M1 cohorts were 100% and 83.3% (95% CI: 58.3%– 100%), respectively. At five years, OS was 94.4% for the M0 cohort.

Conclusion

Administration of standard-dose TPF as induction chemotherapy in this NPC patient population is both feasible and effective when coupled with definitive concurrent chemoradiation. ClinicalTrials.gov identifier NCT00896181 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induction ChemotherapyNasopharyngeal CarcinomaNasopharyngeal NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsBevacizumabChemoradiotherapyCisplatinDocetaxelFluorouracilPlatinum

Substanzen

BevacizumabCisplatinDocetaxelFluorouracilPlatinum

Autor:innen und Institutionen

  • Stanford Cancer Institute, Stanford University, Stanford, California, United States of America.
  • Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California, United States of America.
  • Department of Radiation Oncology, Stanford Cancer Center, Stanford University, Stanford, California, United States of America.
  • Department of Nuclear Medicine & Molecular Imaging, Stanford University Medical Center, Stanford University, Stanford, California, United States of America.
  • Stanford Health Care, Stanford, California, United States of America.
  • Department of Biomedical Data Science, School of Medicine, Stanford University, Stanford, California, United States of America.

ORCID-Profile: Quynh-Thu Le, Rong Lu, A Dimitrios Colevas

Förderung

  • school of medicine, stanford university

Zitieren

APA

Jun, M., Pinto, H., Le, Q. T., Quon, A., Hara, W., Coty, J., McMillan, A., Lu, R., Winters, E., Lira, R., & Colevas, A. D. (2023). In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation. PLOS ONE. https://doi.org/10.1371/journal.pone.0276651

Vancouver

Jun M, Pinto H, Le QT, Quon A, Hara W, Coty J, et al. In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation. PLOS ONE. 2023. doi:10.1371/journal.pone.0276651

BibTeX
@article{Jun2023,
  author = {Jun, Michelle and Pinto, Harlan and Le, Quynh-Thu and Quon, Andrew and Hara, Wendy and Coty, Jessie and McMillan, Alex and Lu, Rong and Winters, Elzbieta and Lira, Ruth and Colevas, A Dimitrios},
  title = {In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0276651}
}
Kostenlos starten →